Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR plus ) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
CANCER RESEARCH（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要